Open AccessSafety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in adults living with HIV
Author(s) -
Lerato Mohapi,
Yvett Pinedo,
Olayemi Osiyemi,
Khuanchai Supparatpinyo,
Winai Ratanasuwan,
JeanMichel Molina,
Ron Dagan,
Gretchen Tamms,
Tina Sterling,
Ying Zhang,
Alison Pedley,
Jon Hartzel,
Yanqing Kan,
Kim Hurtado,
Luwy Musey,
Jakub K. Simon,
Ulrike K. Buchwald
Publication year - 2021
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/qad.0000000000003126
Subject(s) - pneumococcal conjugate vaccine , medicine , pneumococcal polysaccharide vaccine , immunogenicity , adverse effect , streptococcus pneumoniae , vaccination , pneumococcal vaccine , immunology , serotype , viral load , antibody , human immunodeficiency virus (hiv) , microbiology and biotechnology , biology , pneumococcal disease , antibiotics
To evaluate safety and immunogenicity of V114 [15-valent pneumococcal conjugate vaccine (PCV) containing serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F], followed by 23-valent pneumococcal polysaccharide vaccine (PPSV23) 8 weeks later, in adults living with HIV.